paroxetine mesylate / Generic mfg. - LARVOL DELTA

Nonhormonal treatments for vasomotor symptoms. (PubMed, Curr Opin Obstet Gynecol) - "Women who cannot use or wish to avoid hormones have a number of nonhormonal options to choose from to treat hot flashes. New science elucidating the biology of hot flashes holds great promise for highly effective treatments that do not have off-target effects."

Journal

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis. (PubMed, Front Psychiatry) - "As an alternative to hormone replacement therapy, paroxetine mesylate became the only non-hormonal treatment approved by the U.S. Food and Drug Administration (FDA), despite limited evidence for its efficacy. The results herein call into question the actual efficacy of the only FDA approved, non-hormonal treatment for hot flashes by demonstrating that a placebo response accounts for the majority of treatment responses for reductions in both hot flash frequency and severity. The findings provide evidence to reevaluate the use of paroxetine to treat postmenopausal hot flashes and emphasize the importance of considering effective, alternative treatments for vasomotor symptoms."

Clinical • Retrospective data • Review

Fezolinetant (Veozah) for menopausal vasomotor symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. (PubMed, Int J Womens Health) - "To date, paroxetine mesylate remains the only non-hormonal treatment that has been approved by the United States Food and Drug Administration (FDA) for the management of moderate to severe postmenopausal vasomotor symptoms...Knowing potential medication interactions is critical such as with medications that can lead to serotonin syndrome, concomitant use with monoamine oxidase inhibitors and being aware of p450 drug metabolism is essential for patients taking drugs that utilize the CYP2D6 enzyme for metabolism including tamoxifen. This review discusses in detail the available data supporting the use of paroxetine for the treatment of VMS, including side effects and considerations regarding prescribing. A discussion of other emerging treatments is included as well, including estetrol, oxybutynin and neurokinin 3 (NK3) receptor antagonists."

Journal • Review • CNS Disorders • Depression • Fatigue • Mood Disorders • Psychiatry

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

A third of antidepressants aren't prescribed for depression - "Hadine Joffe has worked on a number of such studies for a project called MsFLASH, including a three-armed study comparing the effects on hot flashes of a placebo, low-dose oestrogen or an antidepressant....'It’s not like everyone rushed to use Brisdelle,' says Joffe, noting that insurance companies might be more likely to pay for a generic antidepressant than for a new brand-name drug (generic paroxetine costs $10 a month compared to $200 a month for Brisdelle)."

Media quote • CNS Disorders • Depression

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder (clinicaltrials.gov) - P3; N=5; Terminated; Sponsor: Cedars-Sinai Medical Center; N=15 ➔ 5

Clinical • Enrollment change

Oxybutynin for hot flashes in women with breast cancer. (PubMed, Med Lett Drugs Ther) - No abstract available.

Clinical • Journal